11,939 Shares in Natera, Inc. (NASDAQ:NTRA) Acquired by Bryce Point Capital LLC

Bryce Point Capital LLC bought a new position in Natera, Inc. (NASDAQ:NTRA) in the fourth quarter, Holdings Channel.com reports. The fund bought 11,939 shares of the medical research company’s stock, valued at approximately $1,890,000. Natera accounts for 0.5% of Bryce Point Capital LLC’s investment portfolio, making the stock its 18th biggest holding.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of Natera in the third quarter valued at $385,000. Everence Capital Management Inc. bought a new stake in Natera in the fourth quarter worth about $573,000. Smartleaf Asset Management LLC raised its position in Natera by 50.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company’s stock worth $104,000 after acquiring an additional 220 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Natera by 87.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 67,906 shares of the medical research company’s stock valued at $8,621,000 after acquiring an additional 31,649 shares during the last quarter. Finally, SeaBridge Investment Advisors LLC bought a new position in shares of Natera during the 4th quarter valued at about $2,894,000. 99.90% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Gail Boxer Marcus sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $147.69, for a total transaction of $590,760.00. Following the transaction, the director now owns 9,704 shares of the company’s stock, valued at approximately $1,433,183.76. This trade represents a 29.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John Fesko sold 663 shares of the business’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the completion of the sale, the insider now directly owns 156,044 shares of the company’s stock, valued at $27,739,941.88. This represents a 0.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 318,922 shares of company stock worth $50,619,104 in the last three months. 7.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts recently commented on NTRA shares. Royal Bank of Canada initiated coverage on shares of Natera in a report on Thursday, March 13th. They issued an “outperform” rating and a $251.00 target price on the stock. StockNews.com raised Natera from a “sell” rating to a “hold” rating in a report on Wednesday, March 19th. Guggenheim raised their price objective on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. Piper Sandler boosted their target price on Natera from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 4th. Finally, Morgan Stanley increased their price target on Natera from $176.00 to $185.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $178.12.

Natera Trading Down 0.5 %

Shares of NASDAQ:NTRA opened at $140.65 on Wednesday. The firm has a fifty day moving average of $158.72 and a two-hundred day moving average of $151.35. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 12-month low of $83.13 and a 12-month high of $183.00. The firm has a market capitalization of $19.01 billion, a P/E ratio of -79.91 and a beta of 1.80.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. On average, equities analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.